Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.

Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

SAN FRANCISCO — Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic ...

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma ...

24 abstracts, including 1 oral presentation and 4 late-breaking posters ... with asthma TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ...

Asthma & Immunology annual meeting. "This may suggest that the window of opportunity for catch-up growth may be primarily in the <12 years age group," her group reported in the poster presentation.

Sanofi will present 24 abstracts, including four oral presentations and a late-breaking poster, across approved and investigational medicines at the American Academy of Allergy, Asthma and Immunology ...